thiazolidinediones (TZDs)

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan, David M; Buse, John B; Davidson, Mayer B; Ferrannini, Ele; Holman, Rury R; Sherwin, Robert; Zinman, Bernard
Diabetes care; 2009 Jan;32(1):193-203. PMID: 18945920
Category: 
Interventions
Tags: 
DPP-4 inhibitors
GLP-1 agonists
glycemic control
insulin therapy
lifestyle changes
metformin
sulfonylureas (SUs)
thiazolidinediones (TZDs)

Whose Diabetes Treatment Recommendations are Correct?

Posted March 8, 2012 by Irl B. Hirsch, MD
Tags: 
thiazolidinediones (TZDs)
sulfonylureas (SUs)
prediabetes
metformin
insulin therapy
glycemic control
GLP-1 agonists
DPP-4 inhibitors
Primary care physicians are expected to be experts on dozens of different disease states despite the fact that each medical problem continues to evolve, with new understanding of the disease itself and its treatments. Frankly, I see this as a near impossible task since as an endocrinologist I can barely keep up with diabetes (in reality I can’t).

Tailoring Clinical Practice Guidelines for Patients with Type 2 Diabetes

Posted September 21, 2011 by Sonal Singh, MD, MPH
Tags: 
thiazolidinediones (TZDs)
sulfonylureas (SUs)
metformin
DPP-4 inhibitors
Several guidelines emphasize the need to use existing therapeutic options to help patients and providers achieve various treatment goals, including target glycated hemoglobin levels to improve microvascular outcomes among patients with type 2 diabetes. 1  Blood pressure medications and lipid lowering therapy and prophylactic aspirin therapy are recommended to improve cardiovascular outcomes. Influenza and pneumococcal vaccination strategies are recommended to reduce the risk of subsequent infections.

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.

Bennett, Wendy L; Maruthur, Nisa M; Singh, Sonal; Segal, Jodi B; Wilson, Lisa M; Chatterjee, Ranee; Marinopoulos, Spyridon S; Puhan, Milo A; Ranasinghe, Padmini; Block, Lauren; Nicholson, Wanda K; Hutfless, Susan; Bass, Eric B; Bolen, Shari
Annals of internal medicine; 2011 May 3;154(9):602-13. PMID: 21403054
Category: 
Interventions
Tags: 
thiazolidinediones (TZDs)
sulfonylureas (SUs)
metformin
glycemic control
GLP-1 agonists
DPP-4 inhibitors